Ellagic acid inhibits melanoma growth in vitro


Submitted: 27 August 2011
Accepted: 31 August 2011
Published: 12 December 2011
Abstract Views: 1740
PDF: 771
HTML: 134
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • James Daniel Jensen Department of Dermatology, School of Medicine, University of Colorado, Denver, CO, United States.
  • Jeffrey H. Dunn Department of Dermatology, School of Medicine, University of Colorado, Denver, CO, United States.
  • Yuchun Luo Department of Dermatology, School of Medicine, University of Colorado, Denver, CO, United States.
  • Weimin Liu Department of Dermatology, School of Medicine, University of Colorado, Denver, CO, United States.
  • Mayumi Fujita Department of Dermatology, School of Medicine, University of Colorado, Denver; Denver Veterans's Affairs Medical Center, Denver, CO, United States.
  • Robert P. Dellavalle Department of Dermatology, School of Medicine, University of Colorado, Denver; Denver Veterans's Affairs Medical Center, Denver, CO, United States.
Ellagic is a polyphenolic compound with anti-fibrotic and antioxidant properties as well as exhibits antitumor properties against various cancer cells in vitro. There are few studies, however, which examine the effects of ellagic acid on melanoma. In the present study, we observe effects of ellagic acid on melanoma cells in vitro. Three metastatic melanoma cell lines (1205Lu, WM852c and A375) were examined to determine the effects of ellagic acid on melanoma cell viability, cell-cycle, apoptosis, NF-κβ activity, and IL-1β & IL-8 secretion. Cell viability assays demonstrated that ellagic acid possesses an inhibitory effect on cell proliferation at concentrations between 25 and 100 µM. In addition, ellagic acid promoted G1 cell cycle arrest, increased levels of apoptosis and decreased synthesis of IL-1β and IL-8 in melanoma cells. Ellagic acid also decreased NF-κβ activity, suggesting at least one potential mechanism by which ellagic acid may exert its effects in melanoma cells. Our findings support further investigation into prospective roles for ellagic acid as a therapeutic, adjuvant, or preventive agent for melanoma.

Supporting Agencies

This study was funded by a Startup Grant from the University of Colorado Cancer Center (Dellavalle) and by the Wendy Will Case Cancer Fund (Fujita).

Jensen, J. D., Dunn, J. H., Luo, Y., Liu, W., Fujita, M., & Dellavalle, R. P. (2011). Ellagic acid inhibits melanoma growth in vitro. Dermatology Reports, 3(3), e36. https://doi.org/10.4081/dr.2011.e36

Downloads

Download data is not yet available.

Citations